WO2002072016A3 - Method of preventing adhesions with ifn-¿y? - Google Patents

Method of preventing adhesions with ifn-¿y? Download PDF

Info

Publication number
WO2002072016A3
WO2002072016A3 PCT/US2002/007290 US0207290W WO02072016A3 WO 2002072016 A3 WO2002072016 A3 WO 2002072016A3 US 0207290 W US0207290 W US 0207290W WO 02072016 A3 WO02072016 A3 WO 02072016A3
Authority
WO
WIPO (PCT)
Prior art keywords
ifn
enhancers
preventing adhesions
adhesion formation
event
Prior art date
Application number
PCT/US2002/007290
Other languages
French (fr)
Other versions
WO2002072016A2 (en
Inventor
Michael P Diamond
Ghassan M Saed
Original Assignee
Univ Wayne State
Michael P Diamond
Ghassan M Saed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State, Michael P Diamond, Ghassan M Saed filed Critical Univ Wayne State
Priority to AU2002257027A priority Critical patent/AU2002257027A1/en
Publication of WO2002072016A2 publication Critical patent/WO2002072016A2/en
Publication of WO2002072016A3 publication Critical patent/WO2002072016A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma

Abstract

Methods for the prevention of adhesion formation and development involve the administration of therapeutic formulations to a patient which include, as active ingredients, IFN-y or IFN-y enhancers. The IFN-y or IFN-y enhancers are preferably administered to fibrosis tissues in a subject prior to an event which induces adhesion formation, such as a surgical event.
PCT/US2002/007290 2001-03-13 2002-03-11 Method of preventing adhesions with ifn-¿y? WO2002072016A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002257027A AU2002257027A1 (en) 2001-03-13 2002-03-11 Method of preventing adhesions with ifn-y

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27538101P 2001-03-13 2001-03-13
US60/275,381 2001-03-13

Publications (2)

Publication Number Publication Date
WO2002072016A2 WO2002072016A2 (en) 2002-09-19
WO2002072016A3 true WO2002072016A3 (en) 2003-02-13

Family

ID=23052048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/007290 WO2002072016A2 (en) 2001-03-13 2002-03-11 Method of preventing adhesions with ifn-¿y?

Country Status (2)

Country Link
AU (1) AU2002257027A1 (en)
WO (1) WO2002072016A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US5885829A (en) * 1996-05-28 1999-03-23 The Regents Of The University Of Michigan Engineering oral tissues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US5885829A (en) * 1996-05-28 1999-03-23 The Regents Of The University Of Michigan Engineering oral tissues

Also Published As

Publication number Publication date
AU2002257027A1 (en) 2002-09-24
WO2002072016A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
WO2003080021A3 (en) Formulation comprising buprenorphine
CA2446435A1 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2004112711A3 (en) Oral extended-release composition
WO2006082588A3 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
WO2001095899A3 (en) Pharmaceutical compositions comprising cannabidiol derivatives
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2002089778A3 (en) Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
WO2005065317A3 (en) Effervescent oral fentanyl dosage form
CA2294921A1 (en) Levobupivacaine and its use
HRP20050342B1 (en) Pharmaceutical formulation of olanzapine
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
MXPA05013270A (en) Transmucosal form of administration with reduced mucosal irritation.
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
EP1090635A3 (en) Use of ferulic acid for treating hypertension
WO2003018535A3 (en) Novel aminobenzoephenones
CA2385755A1 (en) Prevention of colorectal cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10471892

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP